Clotting Factor Assey at Dr. Essa Lab

Clotting Factor Assey at Dr. Essa Lab

The Clotting Factor Assey at Dr. Essa Lab is a highly specialized, state-of-the-art diagnostic blood test designed to evaluate the activity and concentration of specific coagulation factors within the human body. Coagulation factors are essential proteins produced primarily by the liver that work in a highly coordinated, sequential cascade to form a stable blood clot at the site of vascular injury. When a blood vessel is damaged, these factors are activated in a step-by-step process known as the coagulation cascade, culminating in the conversion of soluble fibrinogen into insoluble fibrin strands. This fibrin network traps platelets and red blood cells, effectively sealing the wound and preventing excessive blood loss. A deficiency, absence, or dysfunction of even a single clotting factor can severely disrupt this delicate balance, leading to either life-threatening hemorrhages or abnormal, obstructive clot formation (thrombosis).

At Dr. Essa Lab, the Clotting Factor Assey utilizes advanced automated coagulation analyzers that employ photo-optical and mechanical clot detection technologies. By precisely measuring the time it takes for a patient’s plasma to clot in the presence of specific reagents and factor-deficient substrates, our laboratory can pinpoint the exact factor that is deficient or dysfunctional. This test is of paramount clinical importance in diagnosing inherited bleeding disorders, such as Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency), as well as acquired bleeding disorders resulting from liver disease, vitamin K deficiency, or the presence of autoimmune inhibitors. By providing highly accurate, quantitative measurements of factor activity, the Clotting Factor Assey at Dr. Essa Lab serves as an indispensable tool for hematologists, surgeons, and critical care physicians in Karachi and across Pakistan, facilitating precise therapeutic interventions and ensuring optimal patient safety during surgical procedures.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is critical to ensure the clinical accuracy of the Clotting Factor Assey at Dr. Essa Lab, as external variables can significantly influence coagulation times and factor activity levels. Patients are advised to adhere to the following guidelines:

• Medication Review: It is imperative to inform your prescribing physician and the laboratory staff of all medications, over-the-counter drugs, and herbal supplements you are currently taking. Anticoagulants such as warfarin, heparin, low-molecular-weight heparin (LMWH), and direct oral anticoagulants (DOACs like rivaroxaban or apixaban) directly interfere with coagulation assays. Your physician may advise you to temporarily discontinue these medications prior to the test, depending on your clinical situation.
• Fasting Guidelines: While strict fasting is generally not required for a Clotting Factor Assey, patients are strongly advised to avoid consuming fatty or greasy meals for at least 4 to 6 hours before the blood draw. High levels of lipids in the blood (lipemia) can interfere with the photo-optical detection systems used in automated coagulation analyzers, potentially leading to inaccurate results.
• Stress and Physical Activity: Avoid strenuous physical exercise and extreme emotional stress immediately before the test. Physical exertion can temporarily elevate levels of certain clotting factors, particularly Factor VIII and Von Willebrand factor, which may mask a mild underlying deficiency.
• Hydration: Staying well-hydrated by drinking plenty of plain water is highly recommended, as it facilitates easier venous access and ensures a smooth blood collection process.

During the Procedure

The Clotting Factor Assey is performed on a venous blood sample collected by our highly trained phlebotomists at Dr. Essa Lab. The procedure is quick, safe, and follows strict international clinical standards:

• Patient Positioning: You will be asked to sit comfortably in a specialized phlebotomy chair or lie down on an examination table. The phlebotomist will examine your arm to locate a suitable, prominent vein, typically in the antecubital fossa (the crook of the elbow).
• Sanitization and Tourniquet Application: The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) to prevent contamination. A latex-free elastic tourniquet is applied around your upper arm to increase venous pressure, making the vein more visible and accessible. The tourniquet is kept on for less than one minute to prevent hemoconcentration, which can artificially alter clotting factor concentrations.
• Venipuncture and Sample Collection: A sterile, single-use needle is gently inserted into the vein. The blood is drawn directly into a specialized light blue-top vacuum tube containing a precise concentration of buffered sodium citrate (3.2%). The sodium citrate acts as a reversible anticoagulant by binding calcium ions in the blood, thereby preserving the clotting factors in an inactive state until testing begins.
• Tube Inversion and Mixing: Immediately after collection, the phlebotomist will gently invert the tube 3 to 4 times to ensure thorough mixing of the blood with the sodium citrate anticoagulant. Vigorous shaking is strictly avoided, as it can cause hemolysis (rupture of red blood cells) or premature activation of platelets, both of which invalidate the test.
• Duration and Sensation: The entire venipuncture process takes less than two minutes. You may feel a brief, mild pinch or stinging sensation as the needle enters the skin. After the needle is withdrawn, gentle pressure is applied to the puncture site with a sterile cotton ball, followed by the application of an adhesive bandage to prevent bruising.
• Safety and Processing: All equipment used is sterile and disposable, eliminating any risk of infection. The collected sample is immediately sent to the specialized coagulation department of Dr. Essa Lab, where it undergoes controlled centrifugation to separate platelet-poor plasma, which is then analyzed using advanced diagnostic instruments.

When is a Clotting Factor Assey Performed?

Investigating Unexplained Bleeding or Bruising

Physicians frequently order a Clotting Factor Assey when a patient presents with unexplained, prolonged, or recurrent bleeding episodes that cannot be attributed to minor trauma. This includes symptoms such as frequent and severe nosebleeds (epistaxis), bleeding gums without dental disease, unusually heavy or prolonged menstrual periods (menorrhagia), and the easy formation of large, deep bruises (ecchymoses or hematomas) with minimal or no known impact. The assay helps identify whether a specific protein deficiency in the coagulation cascade is responsible for the impaired hemostasis.

Evaluating Prolonged Coagulation Screening Tests

If routine screening tests, such as Prothrombin Time (PT) or Activated Partial Thromboplastin Time (aPTT), yield abnormally prolonged results, a Clotting Factor Assey is indicated as a secondary, diagnostic step. While PT and aPTT indicate that there is a delay in clot formation, they do not specify which factor is lacking. The Clotting Factor Assey systematically measures individual factor activities (such as Factors II, V, VII, VIII, IX, X, XI, and XII) to pinpoint the exact molecular defect causing the prolonged screening times.

Diagnosing Inherited Bleeding Disorders

A Clotting Factor Assey is the definitive diagnostic tool for identifying inherited bleeding disorders in patients with a suggestive family history or early-onset bleeding symptoms. For instance, a selective assay showing significantly reduced Factor VIII activity confirms a diagnosis of Hemophilia A, while a deficiency in Factor IX confirms Hemophilia B. Identifying these genetic deficiencies early in life is crucial for establishing a prophylactic treatment plan, managing bleeding episodes with factor concentrates, and counseling families regarding genetic inheritance patterns.

Assessing Liver Function and Vitamin K Deficiency

Because the liver is the primary site for the synthesis of almost all coagulation factors, a Clotting Factor Assey is highly valuable in evaluating the synthetic capacity of the liver in patients with chronic liver diseases, such as cirrhosis, hepatitis, or acute liver failure. Additionally, Factors II, VII, IX, and X require Vitamin K for their functional activation. Performing this assay helps clinicians differentiate between severe liver parenchymal damage and simple Vitamin K deficiency, guiding appropriate therapy such as Vitamin K supplementation or fresh frozen plasma transfusions.

Monitoring Recurrent Thrombosis or Miscarriages

While most clotting factor assays are performed to investigate bleeding, elevated levels of certain factors (such as Factor VIII, IX, or XI) are associated with an increased risk of abnormal blood clot formation (thrombosis) in deep veins (DVT) or lungs (pulmonary embolism). Furthermore, evaluating clotting factor pathways is essential in investigating women who suffer from recurrent, unexplained pregnancy losses, as subclinical hypercoagulable states can lead to microvascular thrombosis in the placenta, compromising fetal blood supply.

What Does a Clotting Factor Assey Detect?

The Clotting Factor Assey at Dr. Essa Lab is designed to detect a wide range of quantitative and qualitative abnormalities in the coagulation system. Through precise laboratory analysis, this test can detect:

• Factor VIII Deficiency (Hemophilia A): An inherited, X-linked bleeding disorder characterized by a lack of functional Factor VIII, leading to severe bleeding into joints (hemarthrosis) and muscles.
• Factor IX Deficiency (Hemophilia B / Christmas Disease): Another X-linked genetic disorder caused by a deficiency of Factor IX, presenting with clinical symptoms identical to Hemophilia A.
• Factor XI Deficiency (Hemophilia C): An autosomal genetic disorder, more common in certain ethnic groups, characterized by mild to moderate bleeding, often occurring after trauma or surgery.
• Factor XII Deficiency (Hageman Factor Deficiency): A unique condition that prolongs the aPTT in laboratory tests but does not cause clinical bleeding; detecting it prevents unnecessary clinical concern.
• Factor VII Deficiency: A rare autosomal recessive disorder that affects the extrinsic pathway of coagulation, leading to bleeding symptoms ranging from mild epistaxis to severe intracranial hemorrhage.
• Factor II (Prothrombin) Deficiency: A very rare congenital or acquired disorder that impairs the final stages of the clotting cascade, resulting in systemic bleeding tendencies.
• Factor V Deficiency (Owren’s Disease): A rare bleeding disorder that can cause mild to severe mucosal and postsurgical bleeding due to impaired prothrombinase complex formation.
• Factor X Deficiency: A rare coagulation defect that severely impairs both the intrinsic and extrinsic pathways, leading to significant bleeding manifestations.
• Factor XIII Deficiency: A condition where clots form normally but are highly unstable and break down rapidly, leading to delayed wound healing and recurrent bleeding hours or days after an injury.
• Acquired Factor Inhibitors: The presence of neutralizing autoantibodies (inhibitors) directed against specific clotting factors, most commonly Factor VIII, which can cause sudden, severe bleeding in adults.
• Severe Liver Disease: Reduced levels of multiple liver-dependent clotting factors (II, VII, IX, X, V, and XI) due to impaired hepatic synthesis.
• Vitamin K Deficiency: Selective reduction in the functional activity of the Vitamin K-dependent clotting factors (II, VII, IX, and X).
• Disseminated Intravascular Coagulation (DIC): A critical, systemic condition characterized by widespread microvascular clotting that rapidly consumes clotting factors, resulting in severely depleted factor levels and profound bleeding.
• Warfarin Therapy Effects: The therapeutic suppression of Vitamin K-dependent factors, allowing clinicians to assess the biochemical impact of oral anticoagulant therapy.
• Unfractionated Heparin Contamination: The presence of heparin in the blood sample, which can artificially lower factor activity measurements unless neutralized in the laboratory.
• Lupus Anticoagulant Interference: The presence of antiphospholipid antibodies that interfere with phospholipid-dependent clotting assays, which can be identified during the assay process.
• Dysfibrinogenemia: The presence of structurally abnormal fibrinogen molecules that do not polymerize correctly, leading to either bleeding or thrombotic tendencies.
• Afibrinogenemia / Hypofibrinogenemia: The complete absence or severe reduction of fibrinogen (Factor I) in the blood, leading to severe bleeding from birth.
• Combined Factor Deficiencies: Rare genetic conditions, such as combined Factor V and Factor VIII deficiency, which present with unique clinical profiles.
• Hypercoagulable States: Abnormally elevated levels of Factor VIII, IX, or XI, which significantly increase an individual’s risk for venous thromboembolism (VTE).

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that timely diagnostic results are crucial for effective clinical decision-making, especially when managing bleeding disorders or preparing patients for major surgical procedures. The Clotting Factor Assey involves complex, specialized laboratory techniques that require meticulous calibration, control runs, and expert interpretation by our consultant pathologists. Typically, the verified reports for individual clotting factor assays are completed and authorized within 24 to 48 hours of sample collection.

Dr. Essa Lab provides highly convenient, digital access to diagnostic reports to ensure a seamless experience for patients and healthcare providers. Once your report is finalized and verified by our pathology team, you will receive an automated SMS notification on your registered mobile number containing a secure link to download your report. Patients can also access their diagnostic history and download PDF reports directly through the official Dr. Essa Lab website or our dedicated mobile application. For those who prefer physical copies, printed reports can be collected from any of our conveniently located collection centers across Karachi and other major cities.

Clotting Factor Assey Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Factor I (Fibrinogen) Activity	200 – 400 mg/dL (Normal clot formation)	Decreased in afibrinogenemia, severe liver disease, DIC, or primary fibrinolysis.
Factor II (Prothrombin) Activity	50% – 150% of normal activity	Decreased in hereditary deficiency, Vitamin K deficiency, liver disease, or warfarin therapy.
Factor V Activity	50% – 150% of normal activity	Decreased in congenital Factor V deficiency, severe liver disease, or acute DIC.
Factor VII Activity	50% – 150% of normal activity	Decreased in early Vitamin K deficiency, liver disease, warfarin therapy, or congenital deficiency.
Factor VIII Activity	50% – 150% of normal activity	Decreased in Hemophilia A, Von Willebrand disease, or due to acquired Factor VIII inhibitors. Elevated in acute phase reactions.
Factor IX Activity	50% – 150% of normal activity	Decreased in Hemophilia B (Christmas disease), Vitamin K deficiency, or liver dysfunction.
Factor X Activity	50% – 150% of normal activity	Decreased in congenital deficiency, amyloidosis, Vitamin K deficiency, or oral anticoagulant use.
Factor XI Activity	50% – 150% of normal activity	Decreased in Hemophilia C, severe liver disease, or congenital deficiency.
Factor XII Activity	50% – 150% of normal activity	Decreased in Hageman factor deficiency (prolongs aPTT but does not cause clinical bleeding).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Clotting Factor Assey?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified, board-certified consultant pathologists, hematologists, and experienced laboratory technologists specializing in coagulation disorders.
• Patient-Focused Care: We prioritize patient comfort, safety, and convenience at every step of the diagnostic journey, ensuring a compassionate and professional environment.
• Quality Diagnostic Services: Dr. Essa Lab utilizes state-of-the-art, fully automated coagulation analyzers and high-quality reagents to deliver exceptionally precise and reproducible results.
• Professional Reporting: All clotting factor assay results undergo rigorous quality control checks and clinical validation by expert pathologists before release.
• Modern Diagnostic Approach: We employ advanced, evidence-based laboratory methodologies that align with international guidelines for hemostasis and thrombosis testing.
• Comfortable Environment: Our diagnostic centers and collection points are designed to provide a clean, hygienic, and stress-free environment for patients of all ages.
• Convenient Location: With an extensive network of branches and collection centers across Karachi and Pakistan, accessing high-quality diagnostic testing is highly convenient.
• Commitment to Accurate Diagnosis: Established in 1987, Dr. Essa Lab has built a legacy of trust and excellence, continuously striving to provide accurate diagnostic insights that save lives.